that was applied to a large and racially homogenous representative population sample, strongly suggest that CYP2A6 alleles expressing decreased enzymatic activity are not associated with a reduced risk of tobacco dependence or lower levels of cigarette smoking.
Nicotine is metabolized to cotinine by the CYP2A6 enzyme, which is genetically variable. In a recent issue of Nature, Pianezza et al reported that subjects who lacked fully functional CPY2A6 and had decreased nicotine metabolism were protected against becoming tobacco-dependent smokers, and that those smokers having at least one defective CYP2A6 allele (null allele) smoked significantly fewer cigarettes than those with the normal gneotype. 1 To the contrary, in a recent study, London et al reported that smokers with at least one CYP2A6-null allele smoked slightly more than those with the normal genotype, and that there was no difference between these two groups concerning the risk of becoming a smoker. 2 However, they found a trend which suggested that subjects with two CYP2A6-null alleles may have a lower risk of becoming tobacco smokers. In both of the aforementioned studies, the CYP2A6 genotype was identified by the method of Fernandez-Salguero et al, 4 which was recently reported to give erroneous results relative to coumarin hydroxylase phenotype, a probe reaction for the CYP2A6 enzyme. 3 Therefore, we decided to study the association between the CYP2A6 genotype and tobacco smoking by using a new allele-specific PCR genotyping method that identifies the major defective CYP2A6 allele and accurately predicts the phenotype. 3 We have used PCR-primers which specifically amplified exons 1-4 of the CYP2A6 gene without amplifying highly homologous CYP2A13 genes or CYP2A7 genes or CYP2A7 pseudogenes. This 1.8-kb PCR fragment was subsequently used as a template for an allele-specific PCR reaction as described in detail by Oscarson et al. 3 The study population consisted of participants from the Kuopio Ischemic Heart Disease Risk Factory Study (KIHD), a population-based epidemiologic study (participation rate 82.6%) that was begun about 10 years ago to investigate previously unestablished risk factors for myocardial infarction, the progression of atherosclerosis, and other major health outcomes in middle-aged men. 5, 6 Those subjects with one null allele were slightly over-represented among smokers ( Table  1 ). The number of smoked cigarettes per day was almost identical among the subjects with one null 18.4 ± 9.9 17.4 ± 6.2 (mean ± SD)
The effect of CYP2A6-null alleles on tobacco smoking: a P = 0.33 for the difference between the proportion of genotypes (one vs none null allele) among smokers and non-smokers: b P = 0.90 for the difference between the frequency of quitting among subjects with one vs none null alleles. c P = 0.92 for the difference between the amount of smoked cigarettes per day among the subjects with the normal genotype vs those subjects with the null allele.
allele and those having the normal genotype ( Table 1) . None of the 965 subjects had two defective alleles, or CYP2A6 gene deletion. 7 The results indicate that the CYP2A6 genotype does not have any notable effect on the number of smoked cigarettes among smokers, which is contrary to the findings of Pianezza et al, 1 and in line with the report by London et al. 2 Our data also imply that there is no difference in the frequency of null alleles among smokers when compared with non-smokers. Our results do not support the results by London et al, however, for the overrepresentation of subjects with two null alleles among non-smokers, 2 since there were no such individuals among our 965 subjects. Our results strongly suggest that the actual allele frequency of CYP2A6-null alleles is less than 3% among Caucasians, as recently observed among Finnish, Spanish and Swedish populations, 3 and that the frequencies of subjects having null alleles, as reported by Pianezza et al 1 
and London et al
2 (12-24%), are erroneously high because of their genotyping method. 4 Furthermore, the present results are considered to better represent the CYP2A6 genotype frequencies among smokers and non-smokers, because the data were obtained from a large unselected, and representative, racially homogenous population sample. Different studies for the VNTR polymorphism failed to reveal any significant association with bipolar and unipolar affective disorders and it is unlikely that it has a major influence on disease risk. 4 However, the analysis of the association between the 5-HTTLPR polymorphism and susceptibility for several psychiatric diseases (including mood disorders, autism, panic disorder, schizophrenia, Alzheimer's disease, obsessive compulsive disorder, personality traits and depressive symptomatology in mood disorders) in different populations has shown some positive but contradictory findings. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Our own study in the Brazilian population 16 as well as all previous single center analyses in Europe did not reveal any significant association between the serotonin transporter polymorphism and affective disorders or schizophrenia. 5, 12, 13, 17 However, when samples from three different European centers were analyzed together, Collier et al 5 found that the frequency of the low-activity short variant (s) of the 5-HTTLPR was higher among patients with affective disorders than in normal controls. A positive association between this polymorphism and unipolar as well as bipolar patients was also observed by Furlong et al 4 through a meta-analysis including data from several studies. These observations suggest that large samples are required in order to detect significant results.
Analysis
We are not aware, however of previous association studies between the 5-HTTLPR polymorphism and dysthymia. Therefore we have analyzed this polymorphism in a sample of Brazilian patients affected by this disorder as compared to bipolar and major depression patients.
A total of 192 patients were included in the present case-control study: 62 with dysthymia (mean age 40.0 ± 11.5 years), 64 with bipolar disorder (mean age 41.8 ± 12.5 years) and 66 with major depression (mean age 41.3 ± 11.4 years). The patients with dysthymia, bipolar disorder and major depression were selected from the Institute of Psychiatry (Universidade de São Paulo) and the Affective Disorder Unity of the Clinical Hospital (Universidade Federal de Pernambuco). All the patients were diagnosed according to the DSM-IV (APA) and/or CID-10 criteria. Among the patients, about 40% were African/Brazilian, and the remaining 60% were Caucasoids. Normal controls included 152 volunteers who worked at the São Paulo University (or were normal relatives of muscular dystrophy patients without any history of major psychiatric illness) and 45 from the Federal University of Pernambuco with no familial or personal history of psychiatric disorder or treatment, suicide attempt and drug addiction (mean age 38.5 ± 9.8 years). About 50% of the controls were Caucasoids and the remaining were African/Brazilians. The study was approved by the ethical committee from our University and blood samples were drawn from patients and controls after informed consent.
DNA was extracted from blood and the 5-HTTLPR was analyzed by PCR according to the method reported by Lesch et al. 6 According to this method two fragments are generated: the short variant (s) with 484 bp and the long one (L) with 528 bp.
Genotype and gene frequencies were compared among the different groups using chi-squared analysis on contingency tables with allowance for heterogeneity testing and for the analysis of adjusted residuals.
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The results on 5-HTTLPR genotype frequencies in our sample of normal controls and patients are summarized in Table 1 . Allele frequency estimates and corresponding results of chi-squared analysis for HardyWeinberg proportions are summarized in Table 2 .
Pooling all data of Table 1 together, the gene frequency estimates are: P (L) = 0.603 ± 0.017; P (s) = 0.397 ± 0.017 and 
